Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis

Journal of Rheumatology

Volumn 39, Issue 5, 2012, Pages 916-928

  Mesko, Bertalan ^a   Poliska, Szilard ^a,b   Szamosi, Szilvia ^c   Szekanecz, Zoltan ^c   Podani, Janos ^d   Varadi, Csaba ^a   Guttman, Andras ^b   Nagy, Laszlo ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Anti interleukin 6 receptor; Drug response; Gene expression; IgG glycosylation; Tocilizumab

Indexed keywords

GALACTOSE; GLYCAN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PREDNISONE; TOCILIZUMAB;

ARTICLE; CCDC32 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DHFR GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPHA4 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TRAV8-3 GENE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; FEMALE; GENETIC MARKERS; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; TRANSCRIPTOME;

EID: 84860728971     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110961     Document Type: Article

References (19)

1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244-79.
2. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: The interleukin-6 receptor. Rheumatology 2010;49:15-24.
3. Suzuki M, Hashizume M, Yoshida H, Mihara M. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: Effect on the expression of chemokine and adhesion molecule. Rheumatol Int 2010;30:309-15.
4. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: A review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32.
5. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9. (Pubitemid 38725087)
6. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
7. Mesko B, Poliska S, Szegedi A, Szekanecz Z, Palatka K, Papp M, et al. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics 2010;3:15.
8. van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC, Tak PP, Verweij CL. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 2010;62:1602-7.
9. van't Veer LJ, Dai H, van de Vijver MJ, Wesseling J, Nuyten DS, van Krimpen C, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
10. Axford JS, Sumar N, Alavi A, Isenberg DA, Young A, Bodman KB, et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 1992;89:1021-31.
11. Croce A, Firuzi O, Altieri F, Eufemi M, Agostino R, Priori R, et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 2007;21:303-14. (Pubitemid 47556810)
12. Podani J. Introduction to the exploration of multivariate biological data. Leiden: Backhuys; 2000.
13. Podani J. Syn-Tax 2000 computer programs for data analysis in ecology and systematics. User's manual. Budapest: Scientia; 2001.
14. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-a monoclonal antibody, infliximab. Rheumatology 2008;47:780-8. (Pubitemid 351796361)
15. Alavi A, Axford J. Evaluation of beta 1, 4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Glycoconj J 1995;12:206-10.
16. Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 2008;10:277-81. (Pubitemid 351649868)
17. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Singh P, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 2009;19:823-8.
18. Miyazaki E, Kawana-Tachikawa A, Tomizawa M, Nunoya J, Odawara T, Fujii T, et al. Highly restricted T-cell receptor repertoire in the CD8+ T-cell response against an HIV-1 epitope with a stereotypic amino acid substitution. AIDS 2009;23:651-60.
19. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:196-202. (Pubitemid 30064610)